Monoclonal antibodies to thymosin alpha 1.
Stähli. C C; Takács. B B; Kocyba. C C
Key Findings
- Sixteen monoclonal antibodies were generated that recognize the C‑terminal half of thymosin‑alpha‑1.
- Human and fetal calf serum contain substances that cross‑react with this epitope, potentially confounding measurements.
- A straightforward method to eliminate the cross‑reactive material and a sensitive radioimmunoassay (RIA) were developed.
Practical Outcomes
- For biohackers, the study offers no direct guidance on using thymosin‑alpha‑1 for health or performance. Its main value is for researchers needing accurate measurement of the peptide, not for everyday supplementation protocols.
Summary
The paper describes how scientists created antibodies that bind to a specific part of the peptide thymosin‑alpha‑1, discovered that normal blood serum contains substances that can interfere with these antibodies, and introduced a simple way to remove that interference along with a sensitive test to measure the peptide. It doesn’t provide any new health‑related uses or dosing advice for thymosin‑alpha‑1.
Abstract
Sixteen monoclonal antibodies specific for thymosin alpha 1 [Low et al., J. biol. Chem. 254, 981-986 (1979)] obtained from two fusions with the spleens of three mice [Stähli et al., Meth. Enzym. 92, 26-36 (1982b)] all react with an epitope in the C-terminal half of thymosin alpha 1. Human and foetal calf serum contain substances which cross-react with this epitope. A simple procedure to selectively remove the cross-reactive material and a sensitive RIA are described.
Study Information
pubmed
1983
1983-10-01T00:00:00.000Z
10.1016/0161-5890(83)90118-9
10
6